Inst. Holders
1 funds
FOLD
AMICUS THERAPEUTICS, INC.
—
12-mo target$14.50 (+0.1%)
High Impact Filing (9/10)45 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on FOLD right now — valuation, ownership and activity at a glance.
Inst. Value
$14.00
Inst. Activity
0 buys / 45 sells
Social Sentiment
60° Warm
SEC Reports
3
Price chart
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 2, 2026 clinical_trial_readout
T-90d Trial Readout: migalastat HCl 150 mg (Phase 3)
Trial: A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease
Aug 12, 2026 Event
POMBILITI ATGA
WARNING: SEVERE HYPERSENSITIVITY REACTIONS, INFUSION-ASSOCIATED REACTIONS, and RISK OF ACUTE CARDIOR
Jun 30, 2026 Inst.
STATE STREET CORP — EXIT
0 shares ($0.00)
Jun 30, 2026 Inst.
May 7, 2026 SEC Allianz Asset Management GmbH — EXIT
0 shares ($0.00)
Amicus Therapeutics filed a Form 15-12G to deregister its securities following its acquisition by BioMarin Pharmaceutica
15-12G — Impact 4/10
Amicus Therapeutics completed its acquisition by BioMarin Pharmaceutical, resulting in a change of control, delisting fr
8-K — Impact 9/10
Apr 27, 2026 Insider
Campbell Bradley L disposed of 1,008,680 shares
President and CEO @ $14.50 ($14.6M)
Apr 27, 2026 Insider
Campbell Bradley L disposed of 103,578 shares
President and CEO
Analyst ratings buy % -24.6%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Jan 22, 2026 | Jefferies | DOWNGRADE | Hold | 53% |
| Dec 29, 2025 | Leerink Partners | DOWNGRADE | Market Perform | 49% |
| Dec 22, 2025 | Citigroup | DOWNGRADE | Neutral | 55% |
| Dec 19, 2025 | Needham | DOWNGRADE | Hold | 50% |
| Dec 19, 2025 | Cantor Fitzgerald | DOWNGRADE | Neutral | 49% |
| Dec 17, 2025 | Citigroup | INITIATE | Buy | 55% |
| Nov 6, 2025 | JP Morgan | MAINTAIN | Overweight | 55% |
| Nov 5, 2025 | Goldman Sachs | MAINTAIN | Neutral | 54% |
| Sep 18, 2025 | Needham | UPGRADE | Buy | 50% |
| Jul 17, 2025 | Morgan Stanley | UPGRADE | Overweight | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 2 | 4 | 8 | 0 | 0 | 43% | |
| Apr 1, 2026 | 2 | 4 | 8 | 0 | 0 | 43% | |
| Mar 1, 2026 | 2 | 4 | 8 | 0 | 0 | 43% | |
| Feb 1, 2026 | 2 | 4 | 8 | 0 | 0 | 43% | |
| Jan 1, 2026 | 4 | 4 | 6 | 0 | 0 | 57% |
Price targets
Where 5 covering analysts think FOLD trades over the next 12 months.
$14.50 +0.1% upside Hold
Current$14.49 Low$14.50 Median$14.50 High$14.50 5 analysts
$14.50$14.50
Analyst rating Hold· 3.0/5 as of Jun 26, 2026
Social media sentiment
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
60°
Warm
BearishNeutralBullish
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
3 SEC filing reports analyzed · 0 bullish, 0 bearish, 0 mixed, 3 neutral · avg impact 6.3/10.
NEUTRAL15-12G4/10
Amicus Therapeutics filed a Form 15-12G to deregister its securities following its acquisition by Bi
May 7, 2026
NEUTRAL8-K9/10
Amicus Therapeutics completed its acquisition by BioMarin Pharmaceutical, resulting in a change of c
Apr 27, 2026
NEUTRAL8-K6/10
Amicus Therapeutics announced that the French Ministry of Economics and Finance has granted foreign
Apr 23, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 2, 2026
Clinical Trial
A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease
Phase Phase 3 — ACTIVE_NOT_RECRUITING
Oct 2, 2026
clinical_trial_readout
T-90d Trial Readout: migalastat HCl 150 mg (Phase 3)
Trial: A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease Sponsor: Amicus Therapeutics Phase: Phase 3 | Stat
Aug 12, 2026
FDA
POMBILITI ATGA
WARNING: SEVERE HYPERSENSITIVITY REACTIONS, INFUSION-ASSOCIATED REACTIONS, and RISK OF ACUTE CARDIORESPIRATORY FAILURE IN SUSCEPTIBLE PATIENTS Hyperse
Jul 29, 2026
earnings_calendar
FOLD Q2 2026 Earnings Scheduled — 2026-07-29
May 13, 2026
earnings_calendar
FOLD Q1 2026 Earnings Scheduled — 2026-05-13
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current FY | $0.07 | $0.07–$0.07 | -76.6% | -88.8% | 0↑ 1↓ | $0.8B | 1 |
| Next FY | $0.82 | $0.47–$0.97 | 1028.8% | -10.8% | 0↑ 1↓ | $0.9B | 4 |
| Next Q | $0.02 | $0.02–$0.02 | 57.1% | -89.6% | 0↑ 1↓ | $0.2B | 1 |
| Current Q | $-0.08 | $-0.08–$-0.08 | -372.8% | -188.0% | 0↑ 1↓ | $0.2B | 1 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.082 | — |
| 7d ago | $0.093 | -0.175 |
| 30d ago | $0.093 | -0.175 |
| 60d ago | $0.093 | -0.175 |
| 90d ago | $0.093 | -0.175 |
Institutional ownership
Which big funds own FOLD (from quarterly 13F filings) and who is adding or trimming.
1 institutional holders with $14.00 total value (1 shares) as of 2026-Q2. Top holders: HUNTINGTON. Net selling activity: 45 institutions trimmed/exited vs 0 added.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| HUNTINGTON NATIONAL BANK | 1 | $14.00 | 100.0% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| STATE STREET CORP | EXIT | 12,893,897 | 0 | -100.0% | $0.00 |
| Allianz Asset Management GmbH | EXIT | 1,441,683 | 0 | -100.0% | $0.00 |
| Magnetar Financial LLC | EXIT | 3,986,058 | 0 | -100.0% | $0.00 |
| PICTON MAHONEY ASSET MANAGEMENT | EXIT | 1,330,842 | 0 | -100.0% | $0.00 |
| GEODE CAPITAL MANAGEMENT, LLC | EXIT | 8,535,918 | 0 | -100.0% | $0.00 |
| JPMORGAN CHASE & CO | EXIT | 6,749,190 | 0 | -100.0% | $0.00 |
| FMR LLC | EXIT | 1,753,843 | 0 | -100.0% | $0.00 |
| MORGAN STANLEY | EXIT | 6,998,884 | 0 | -100.0% | $0.00 |
| BANK OF AMERICA CORP /DE/ | EXIT | 3,899,490 | 0 | -100.0% | $0.00 |
| GOLDMAN SACHS GROUP INC | EXIT | 11,556,008 | 0 | -100.0% | $0.00 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
14 insiders, 50 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 27, 2026 | Campbell Bradley L | President and CEO | D | 1,008,680 | $14.50 | $14.6M |
| Apr 27, 2026 | Campbell Bradley L | President and CEO | D | 103,578 | — | — |
| Apr 27, 2026 | Harford Simon N.R. | Chief Financial Officer | D | 143,595 | $14.50 | $2.1M |
| Apr 27, 2026 | Harford Simon N.R. | Chief Financial Officer | D | 189,043 | — | — |
| Apr 27, 2026 | Castelli Jeff | Chief Development Officer | D | 427,089 | $14.50 | $6.2M |
| Apr 27, 2026 | Castelli Jeff | Chief Development Officer | D | 82,644 | — | — |
| Apr 27, 2026 | Clark David Michael | Chief People Officer | D | 221,811 | $14.50 | $3.2M |
| Apr 27, 2026 | Clark David Michael | Chief People Officer | D | 84,842 | — | — |
| Apr 27, 2026 | Rosenberg Ellen | Chief Legal Officer | D | 463,898 | $14.50 | $6.7M |
| Apr 27, 2026 | Rosenberg Ellen | Chief Legal Officer | D | 93,663 | — | — |
All FOLD filing & press-release reports (3)
- 15-12G reportMay 7, 2026
- 8-K reportApr 27, 2026
- 8-K reportApr 23, 2026